Codex DNA Inc (DNAY) is a biotechnology company that provides synthetic DNA products, technologies, and services. Its flagship product, BioXp™ system, enables rapid and accurate DNA synthesis and assembly, facilitating a wide range of applications, including gene synthesis, genome editing, and personalized medicine.
As of market close on March 4, 2023, the current market capitalization for DNAY is approximately $811 million.
Codex DNA has been expanding its product offerings and partnerships, including collaborations with leading biotechnology and pharmaceutical companies, as well as the launch of its synthetic biology platform, Gibson Assembly®. The company aims to continue driving innovation in synthetic DNA technology, with the goal of advancing research and development across multiple industries, including healthcare, agriculture, and energy.
As with any investment, it's important to conduct your own research and consider your own risk tolerance before making any decisions.
|
